Stevens-Johnson Syndrome from SSRIs
Yes, SSRIs can cause Stevens-Johnson syndrome (SJS), though it is rare, and immediate discontinuation of the suspected SSRI is the most critical intervention to prevent progression to life-threatening toxic epidermal necrolysis (TEN).
Can SSRIs Cause SJS?
SSRIs are documented causes of SJS/TEN, though the association is uncommon. Multiple SSRIs have been implicated:
- Fluoxetine has been specifically associated with potential SJS risk 1, 2
- Fluvoxamine has documented cases of SJS/TEN 2
- Paroxetine has been reported to cause severe cutaneous reactions 2
- Citalopram has been linked to keratinocyte necrosis and dermal leukocytoclastic vasculitis 2
- Sertraline showed increased psychiatric symptom reporting but dermatological reactions were documented 3
The evidence suggests cross-reactivity between different SSRIs despite their different chemical structures 1, 2. This means if one SSRI causes SJS, switching to another SSRI is contraindicated—you must use a different class of antidepressant entirely 1, 2.
Recognition and Diagnosis
Timeline and Presentation
The latent period between drug initiation and SJS/TEN onset is typically 5-28 days after starting the medication 4. Look for:
- Prodromal symptoms: fever, malaise, upper respiratory symptoms 4
- Painful rash initially on face and chest 4
- Mucosal involvement: eyes, mouth, nose, genitalia 4
- Target lesions (particularly atypical targets), purpuric macules, blisters, and epidermal detachment 4
Diagnostic Workup
When SJS is suspected 4:
- Skin biopsy from lesional skin adjacent to blister for histopathology
- Second biopsy from periblister lesional skin (unfixed) for direct immunofluorescence to exclude immunobullous disorders
- Full blood count, liver/kidney function, coagulation studies, mycoplasma serology
- Chest X-ray
- Document extent of erythema and epidermal detachment separately on body map using Lund and Browder chart
- Photograph skin lesions
Histopathology shows: multiple apoptotic keratinocytes throughout full-thickness epidermis, subepidermal split forming bulla, perivascular lymphocytic infiltrate 4
Immediate Management
Critical First Steps 4
Discontinue the suspected SSRI immediately—this is the single most important intervention. Do not wait for confirmatory testing.
- Stop all potential culprit drugs immediately
- Establish IV access through non-lesional skin if possible
- Begin fluid resuscitation if clinically indicated with strict fluid charting
- Insert nasogastric tube if patient cannot maintain oral hydration/nutrition
- Insert urinary catheter if urogenital involvement causes dysuria/retention (also permits accurate output monitoring)
Prognostic Assessment
Use SCORTEN to predict mortality risk 4. One point for each parameter:
- Age >40 years
- Malignancy
- Heart rate >120 bpm
- Initial BSA detachment >10%
- Serum urea >10 mmol/L
- Serum glucose >14 mmol/L
- Serum bicarbonate <20 mmol/L
Higher scores predict higher mortality—this guides intensity of care and need for ICU/burn unit transfer.
Specialized Care
Transfer to intensive care unit or burn center for severe cases 4. Early transfer to specialist units improves outcomes; delayed transfer is associated with increased mortality 4.
Critical Pitfalls
- Do NOT rechallenge with any SSRI if SJS occurred—cross-reactivity means all SSRIs are contraindicated 1, 2
- Do NOT delay drug discontinuation waiting for biopsy results—clinical suspicion is sufficient 4
- Do NOT underestimate mucosal involvement—examine all mucosal sites systematically 4
- Do NOT confuse with erythema multiforme major—SJS has more extensive mucosal involvement and different distribution 4
Long-term Considerations
After recovery, the patient must:
- Avoid the culprit SSRI permanently and all drugs in the same class 4
- Carry documentation of the drug allergy
- Be monitored for chronic sequelae including ocular complications (most common), which benefit from early ophthalmology referral 4
If antidepressant therapy remains necessary, switch to a different class entirely (e.g., tricyclics, bupropion, mirtazapine if not previously implicated) 1, 2.